Consider These Dividend-Paying Stocks During Inflationary Times.Three Upgrades You Need To Pay Attention Too.Get a free copy of the research report on Charles River Laboratories International (CRL).It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). Institutional investors and hedge funds own 93.06% of the company’s stock.Ĭharles River Laboratories International Company Profile ( Get Rating)Ĭharles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. Eaton Vance Management now owns 139,862 shares of the medical research company’s stock valued at $57,492,000 after acquiring an additional 15,088 shares during the period. Finally, Eaton Vance Management boosted its holdings in Charles River Laboratories International by 12.1% during the 3rd quarter. Gotham Asset Management LLC now owns 6,558 shares of the medical research company’s stock valued at $2,706,000 after acquiring an additional 1,268 shares during the period. Gotham Asset Management LLC boosted its holdings in Charles River Laboratories International by 24.0% during the 3rd quarter. Guggenheim Capital LLC now owns 21,752 shares of the medical research company’s stock valued at $8,977,000 after acquiring an additional 1,619 shares during the period. Guggenheim Capital LLC boosted its holdings in Charles River Laboratories International by 8.0% during the 3rd quarter. Ensign Peak Advisors Inc now owns 6,877 shares of the medical research company’s stock valued at $2,838,000 after acquiring an additional 3,487 shares during the period. Ensign Peak Advisors Inc boosted its holdings in Charles River Laboratories International by 102.9% during the 3rd quarter. Morgan Stanley now owns 238,865 shares of the medical research company’s stock worth $88,361,000 after purchasing an additional 71,153 shares during the period. Morgan Stanley boosted its holdings in shares of Charles River Laboratories International by 42.4% in the 2nd quarter. Company insiders own 1.10% of the company’s stock.Ī number of hedge funds and other institutional investors have recently added to or reduced their stakes in CRL. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Following the completion of the transaction, the director now owns 4,677 shares in the company, valued at approximately $1,080,199.92. The stock was sold at an average price of $230.96, for a total transaction of $41,110.88. In other Charles River Laboratories International news, Director George Massaro sold 178 shares of the firm’s stock in a transaction that occurred on Monday, May 9th. The company has a current ratio of 1.34, a quick ratio of 1.12 and a debt-to-equity ratio of 1.02. The stock has a fifty day simple moving average of $252.12 and a two-hundred day simple moving average of $298.94. The company has a market cap of $11.15 billion, a price-to-earnings ratio of 26.74, a price-to-earnings-growth ratio of 1.35 and a beta of 1.27. Charles River Laboratories International has a 12-month low of $214.67 and a 12-month high of $460.21. According to data from MarketBeat, Charles River Laboratories International has an average rating of “Buy” and an average price target of $386.17.ĬRL opened at $219.50 on Monday. Four investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. They noted that the move was a valuation call. They set a “neutral” rating on the stock. Finally, Guggenheim started coverage on Charles River Laboratories International in a research report on Monday, May 23rd. Wells Fargo & Company dropped their price objective on Charles River Laboratories International from $390.00 to $325.00 and set an “overweight” rating on the stock in a research report on Monday, April 25th. Jefferies Financial Group cut Charles River Laboratories International from a “buy” rating to a “hold” rating and dropped their price objective for the company from $370.00 to $280.00 in a research report on Monday, April 25th. Citigroup raised Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $400.00 target price on the stock in a research note on Thursday, February 17th. They issued an “overweight” rating and a $377.00 target price on the stock. Stephens initiated coverage on Charles River Laboratories International in a research note on Wednesday, April 6th. Other equities research analysts have also recently issued reports about the company.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |